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Abstract
This ethics committee–approved pilot study was carried out with informed consent. A protocol was developed
to assess the feasibility of in vitro Microfil injection of prostate cancer specimens followed by analysis with micro-
computed tomography (microCT) to characterize the functional vascularity of prostatic tissue and evaluate its safety
with respect to the preservation of a specimen for pathologic examination. The visible prostatic arteries of two sur-
gically resected prostates frompatients with known prostate cancer (PCa) were injectedwithMicrofil MV-122 contrast
medium immediately after removal. The specimens were scanned using microCT and were qualitatively examined
using three-dimensional analysis software (MicroView; GE Healthcare Biosciences). The Microfil perfusion in the
two samples was sufficient to view the functional vascularity arising from a major prostatic artery, up to a resolution
of 17.626 μm without any indication of adverse effects due to Microfil injection. Malignant prostatic regions showed
a greater vascular density on histology but decreased vascular perfusion compared with benign prostatic regions.
The use of microCT on Microfil-injected prostates seems to be a feasible and specimen-preserving method for visu-
alizing the three-dimensional vessel patterns present in resected human prostates.
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Introduction
Many techniques using different cross-sectional modalities are cur-
rently being evaluated for the image-guided treatment of prostate can-
cer. Two of these use ultrasound and magnetic resonance imaging
(MRI), combined with contrast agents [1,2]. One of the major limit-
ing factors of these techniques is uncertainty regarding their ability to
delineate the functional (patent) vascularity of prostate cancer (PCa).
This study uses a low-viscosity radiopaque polymer, Microfil
MV-122 (Flow Tech, Inc, Carver, MA), which is ideal for enabling
more accurate assessments of prostatic patent angioarchitecture.
Microfil has the advantage of being easy to handle compared with
other contrast agents such as barium sulfate in gelatin; this is because
Microfil’s contrast particles do not settle as quickly, permitting more
time for accurate and thorough vascular perfusion. Furthermore, use
of Microfil avoids the tissue degradation and vessel loss due to breakage,
which is commonly associated with vessel enhancement achieved
through vascular cast corrosion [3]. Microfil has previously been used
to characterize the importance of vascular endothelial growth factor in
angiogenesis during tumor proliferation and maintenance [4] and to
reveal morphologic differences in splenic tumor angiogenesis [5]. The
compound has also been combined with microcomputed tomography
(microCT) to demonstrate the high visual correlation with results
from a T1-weighted MRI scan in a mouse’s brain tumor vasculature
[6] as well as to assess the functional vasculature in a mouse model
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of PCa [7]. The angioarchitecture of many human cancers have been
investigated with Microfil including an angiodysplastic right colon [8],
superficial esophageal carcinoma [9], renal clear cell carcinoma [10],
and small liver metastases [11]. The studies that included histologic
analyses after Microfil injection did not report any adverse effects on
the pathologic specimens [10,11]. Despite the wide range of studies,
there is no report regarding the feasibility and safety of using and ana-
lyzing the in vitro Microfil-injected human prostate.
This study will evaluate the feasibility and safety of using Microfil
and microCT to visualize the patent vascularity of human prostate
specimens. Such information could help increase the sensitivity and
specificity of vascularity-dependent imaging techniques and improve
diagnostic and therapeutic capabilities.
Materials and Methods
Radical prostatectomy specimens were acquired from two consenting
males aged 62 and 63 years, who had biopsy-proven prostate cancer,
after ethics approval was obtained.
Prostatectomies were conducted using standard open-surgery tech-
niques. Surgeons were specifically asked to staple or suture any visi-
ble superficial vessels seen on the prostate to allow them to be more
easily detected. Prostatic arteries were dissected within 30 to 60 min-
utes after prostatectomy; a dissecting microscope was sometimes use-
ful in confirming a vessel lumen or in distinguishing between veins
and arteries. Arteries could often be distinguished from veins due to
their thicker, white vascular walls. Branches of the prostatic arteries
on the prostate’s anterolateral surface [12] were cannulated with
blunt-ended 27-gauge cannulae in the direction that would permit
fluids to be injected intraprostatically; typically, for vessel lumens
near the prostate surface, the cannulae would be oriented in a medial-
posterior direction.
Immediately after cannulation, heparinized saline (20°C, 400 IU/ml)
was manually injected through the cannulae, at a pressure that offered
slight resistance. This was done to avoid ex vivo coagulation and per-
formed until the perfusate was free of blood; approximately 200 ml
was used to achieve this. The heparinized saline was also used to rinse
the specimen’s external surface to remove extraneous blood.
At this point, the low-viscosity Microfil was prepared in a syringe by
mixing 5 ml of Microfil MV-122 with 5 ml of diluent, as well as 1 ml
of curing agent that had been heated to ∼40°C. The syringe was then
attached to the manual pump setup.
The pump was used to maintain a pressure of 120 to 180 mm Hg,
which is similar to the pressures used by other Microfil-using research-
ers to effectively perfuse other organs at a similar viscosity to blood
[3,4,13] and is within the 100- to 200-mm Hg range that Clegg
[14] used when he characterized the prostate vasculature with an
injected barium sulfate compound. The physiological-like pressure
range was used to perfuse the Microfil into the prostate specimen,
through branches of the prostatic arteries. Each cannulated vessel
was serially attached to the syringe and had Microfil pumped through
it, in an attempt to ensure optimal Microfil perfusion into the pros-
tatic vessels. Microfil was injected until it was seen continuously
exiting the prostate from other open vessels on the surface of the pros-
tate, or until there was enough backward pressure on the cannula to
begin to cause the ejection of the cannula. Periodic movement of the
cannula to different vessel depths, and recannulating the same vessel,
allowed the user to ensure that the tip of the cannula was not ob-
structed by a vessel wall and to confirm that the Microfil had not
yet cured and was still flowing.
There is an approximately 20-minute window of working time
before the Microfil will cure based on the composition described.
Once the Microfil had cured in the syringe and was no longer flow-
ing out of the cannula, the specimen sat for an additional 60 minutes
to guarantee that the remaining contrast agent would cure. At this
point, formalin was applied to rinse off the remaining surface-bound
Microfil, in addition to fixing the specimen for 2 to 6 days. During
this period, microCT scans of the specimen were performed in air
using an Inveon CT Module (Siemens Medical Solutions, Erlangen,
Germany). The scanning parameters used were as follows: kilovolt
(peak) = 80 keV, x-ray tube current = 0.5 mA, exposure = 3500
to 3900 milliseconds per view, magnification = low, voxel size =
26.263 μm × 26.263 μm × 26.263 μm (one prostate was scanned
at 17.626 μm × 17.626 μm × 17.626 μm), number of views =
360 degrees over 360 degrees, scan time = ∼24 minutes, number of
reconstructed voxels = 2048 × 2048 × 2272 (max z-axis value =
3072), and reconstruction time = ∼6 hours.
The resultant microCT images were reconstructed three-dimensionally,
and the vascular patterns were examined usingMicroView (GEHealth-
care Biosciences, Buckinghamshire, UK).
After the microCT scans, the prostatectomy specimens were sec-
tioned and histologically examined by a pathologist (L.S.). This was
done to stage and grade the PCa and, with the use of CD31 immuno-
histochemistry markers, to identify any adverse tissue effects due to the
presence of the Microfil. Moreover, the CD31 staining allowed the
quantification of vessel densities at 40× magnification in both benign
and malignant tissues; vessels were registered regardless of whether they
were associated with a visible lumen. Gross pathology and histologic
pictures were acquired and reviewed at 10× magnification to demon-
strate the presence and patterns of vascular Microfil.
Results
Two radical prostatectomy specimens were successfully perfused with
the Microfil.
Figure 1A shows the gross appearance of one of the prostate speci-
mens that was successfully perfused on one side using the Microfil
compound. Two of the anterolateral prostatic vessels were identified
and cannulated on one side to achieve the perfusion. When examined
using microCT, a corkscrew-like appearance was noted in some sur-
face vessels. These vascular patterns agree with observations originally
described by Clegg [14], who regarded them as being associated with
benign tissues and possibly due to smooth muscle variations in those
regions. Figure 1B shows a coronal section of the same prostate that was
injected unilaterally with the Microfil. Findings from the other prostate
resembled those of Figure 1A, particularly regarding the presence of
prostatic surface vessels displaying corkscrew-like patterns.
Figure 2 shows a three-dimensional microCT maximum-intensity
projection of the prostate in Figure 1, injected unilaterally with the
Microfil. It is evident that there is widespread vascularization infiltrat-
ing into one side of the prostate specimen. The vascularization pattern
also supports the idea of end-capillary angioarchitecture [12], as each
cannulation site supplied its own set of vessels. It is believed that the
smaller vessels where Microfil was seen exiting from, after injection
of the Microfil into a cannulated vessel, are branches off the main can-
nulated vessel that had tunneled to the prostate surface and opened up
(through trauma) during the prostate resection.
Histologic analysis of the specimens for grading and staging of
PCa was also achieved, without any indication of adverse effects from
this study’s technique. Microfil-laden vessels in the vicinity of both
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malignant and benign tissues were seen in the specimens, revealing
vessel diameters as small as 18 μm. Areas of higher Microfil perfusion
tended to involve nonmalignant tissue exhibiting 3 to 79 Microfil-
containing vessels per 25 fields at 10× power, whereas areas of
reduced Microfil perfusion were often seen in malignant tissues rang-
ing from as few as 1 Microfil-containing vessel per 14 fields to as
high as 8 Microfil-containing vessels per 25 fields at 10× power (P =
.066) (Table 1). The number of fields examined for malignant tissue
was different from benign tissue because of the paucity of Microfil-
containing malignant vessels. Although the dissimilarities in Microfil-
containing vessel densities did not reach significant statistical difference,
it suggests a trend, and the lack of significant difference could be re-
lated to the small sample size. Furthermore, at 40× magnification,
increased vascular density was apparent in malignant versus benign
CD31-stained prostatectomy tissues. On average, there were approxi-
mately 60 vessels in malignant tissues compared to approximately
33 vessels in benign tissues, per 40× high-power field (P < .0001)
(Table 2). It was also observed that many vessels in the malignant
areas, as demonstrated by CD31 immunostaining, were very tiny
and did not possess readily identifiable lumens.
Figure 3 demonstrates the appearance of Microfil within intra-
prostatic vessels. The Microfil appears black due to the hematoxy-
lin-eosin staining. It also appears shrunken in the vessels, which is
attributed to the pathologic processing of the specimen. The fact that
the blood found in the lumen of vessels, which had not been cleared
with the heparin-saline solution, was shrunken away from the vessel
walls supports this, in addition to the observations of shrunken
Microfil in the histologic images acquired from other researchers
[5,8,11]. No visible signs of Microfil leakage into the interstitial
space or lymphovascular channels were observed histologically—if
this had occurred in the former, it is expected that the Microfil would
be readily seen in pooled non–tubular-shaped conformations.
Discussion
Several studies have attempted to characterize the prostatic vasculature.
However, few offer techniques that are both effective and safe. Slojewski
et al. [15] injected a prostate specimen containing PCa using a techni-
cally difficult and time-consuming procedure involving finely ground
barium sulfate, which required three times as many unsuccessful at-
tempts for every successfully injected prostate. Neumaier et al. [12],
who used color Doppler ultrasound to examine prostate vasculature
in vivo, found that their technique was problematic due to interference
caused by tissues and vessels surrounding, and preceding, the prostatic
vessels. The use of Microfil and microCT in the current study avoids
such problems because Microfil is nontoxic and microCT readily dis-
tinguishes between opaque Microfil-injected vessels and their sur-
rounding less-dense tissues.
Figure 2. Three-dimensional microCTmaximum-intensity projection
of a prostate unilaterally injected with Microfil into a branch of the
prostatic artery. The central nodular densities are believed to be
artifacts, as they were located in a benign area of the prostate speci-
men and no pathology equivalent was observed.
Figure 1. (A) Gross specimen of a prostate, unilaterally injected with Microfil MV-122. Arrow tip indicates superficial vessels perfused
with Microfil MV-122 (yellow). (B) Gross specimen of a coronal section of a prostate, unilaterally injected with Microfil MV-122 into a
branch of the prostatic artery. Arrow tip indicates capsular vessel perfused with Microfil MV-122 (yellow).
Table 1. Quantification of Microfil-Containing Vessels at 10× Magnification, from Two Microfil-
Injected Prostatectomy Specimens.
[Number of Microfil-Containing Vessels] / [Number of Fields] at 10× Power
Specimen 1 Specimen 2 Mean ± SD
Malignant tissues 1/14, 1/14, 1/14 8/25, 8/25, 5/22 [4.51 ± 3.1] / 25
Benign tissues 13/25, 4/25, 9/25, 3/25,
79/25, 10/25
12/25, 12/25, 16/25, 57/25 [21.5 ± 25.4] / 25
Random samples from both malignant and benign tissues were assessed for each prostatectomy
specimen, with a variable number of fields counted per slide. t9 = 2.09, P = .066.
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In this study, the vessels observed on microCT could be as small
as 17.626 μm in diameter. This is much more sensitive than other
techniques such as power Doppler, which has a detection limit of
∼100 to 150 μm [7]. It has been found that, in androgen-dependent
Shionogi carcinomas, which may resemble the androgen-sensitive
PCa tissues, vessels ranged in size from 4.3 to 143 μm with average
diameters of 20 μm [16]. Consequently, this study’s technique could
provide an accurate display of the patent angioarchitecture in PCa tis-
sues. It is important to note that large amounts of computer storage
and power are also necessary to process the higher-resolution images
achievable with this protocol. In our case, one specimen scanned with
17.626 μm voxel resolution required more than 20 GB of storage space
and could only be viewed in sections as the entire specimen required a
minimum of 20.032 GB of RAM to be viewed in MicroView.
There were no visible adverse effects on the specimens due to the
Microfil, and no signs of Microfil leakage into the interstitial space
or lymphovascular channels were observed histologically. Potential
problems with identifying and correctly cannulating branches of the
prostatic arteries will resolve once more specimens are assessed, and
familiarity is acquired, with this technique.
Comparisons of the microvascular densities of benign and malignant
foci using CD31 staining showed higher microvascular density in the
malignant tissues, which reached statistical significance (P < .0001).
However, there was reduced Microfil-laden vessels in the malignant tis-
sues compared with benign, and although this did not reach statistical
significance (P = .06), likely because of the small sample size, it suggests
a trend. This may be due to abnormal heterogeneous vasculature (i.e.,
vessel angulations) and microenvironments (i.e., elevated interstitial
fluid pressures) expected in malignant tissues [17]. Nonpatent malig-
nant vascular lumens are another possibility because only 20% of
tumor vessels may be actually patent [18]. This is supported by this
study’s findings, which revealed that many CD31-immunostained ves-
sels in malignant regions were very tiny and did not have an apparent
lumen. Such traits are alleged to perpetuate angiogenesis through het-
erogeneous perfusion and hypoxia and are often pathognomonic for
malignant vascular networks [9–11]. This observed tissue-dependent
nature of prostatic patent angioarchitecture is expected to be further
defined as more data are gathered with the use of the Microfil tech-
nique. The potential presence of functionally nonpatent vessels in
PCa despite increased microvessel density has implications in the use
of contrast-enhanced imaging to evaluate prostate cancer vascularity,
especially if an intravascular contrast agent is used, such as in dynamic
contrast-enhanced MRI.
In summary, our protocol provides a safe technique for the high-
resolution examination of the functional vasculature of prostate speci-
mens. This protocol preserves the surrounding tissues so that the
specimens may still undergo pathologic processing necessary for grading
and staging of the cancer after their vascular assessment. The fact that
this study’s protocol focuses on the functional vasculature could enable
more definitive conclusions to be drawn with regard to the vascularity
of a tumor seen on imaging, compared with the mean vascular density
that identifies both patent and nonpatent vessels. Quantitative analyses
of such patterns can be easily achieved using microCT images, which
are able to capture a precise cast of the angioarchitecture of prostate
specimens. Analysis of larger numbers of specimens using this protocol
could provide more definitive data to recognize, and potentially predict,
malignant from benign prostatic tissues to aid imaging distinction.
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